title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - Climb Bio  ( NASDAQ:CLYM ) ",20241111T120000,https://www.benzinga.com/pressreleases/24/11/g41875065/climb-bio-appoints-douglas-e-williams-ph-d-as-chair-of-the-board,BIIB,0.111488,Neutral,-0.048758
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board",20241111T120000,https://www.globenewswire.com/news-release/2024/11/11/2978194/0/en/Climb-Bio-Appoints-Douglas-E-Williams-Ph-D-as-Chair-of-the-Board.html,BIIB,0.066877,Neutral,-0.045153
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal,20240904T153200,https://www.zacks.com/stock/news/2331539/atha-stock-tanks-as-alzheimers-study-fails-to-meet-primary-goal,BIIB,0.328455,Bullish,0.369796
Eli Lilly  ( LLY )  Gets FDA Nod for Alzheimer's Drug Donanemab,20240703T123400,https://www.zacks.com/stock/news/2296481/eli-lilly-lly-gets-fda-nod-for-alzheimers-drug-donanemab,BIIB,0.219809,Somewhat-Bullish,0.251132
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?,20240619T170000,https://www.zacks.com/stock/news/2290613/can-eli-lilly-etfs-surge-on-approval-of-alzheimers-drug,BIIB,0.250386,Neutral,0.060737
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab  ( Revised ) ,20240614T152100,https://www.zacks.com/stock/news/2288637/alzheimers-in-focus-as-fda-panel-endorses-lillys-donanemab-revised,BIIB,0.421485,Somewhat-Bullish,0.298879
"The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune  ( Revised ) ",20240614T151000,https://www.zacks.com/stock/news/2288638/the-zacks-analyst-blog-highlights-biogen-eli-lillys-prothena-and-ac-immune-revised,BIIB,0.422897,Somewhat-Bullish,0.251811
"The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune",20240613T100900,https://www.zacks.com/stock/news/2287623/the-zacks-analyst-blog-highlights-biogen-eli-lillys-prothena-and-ac-immune,BIIB,0.431554,Somewhat-Bullish,0.255128
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab,20240612T142200,https://www.zacks.com/stock/news/2287324/alzheimers-in-focus-as-fda-panel-endorses-lillys-donanemab,BIIB,0.431065,Somewhat-Bullish,0.303139
"The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity",20231212T141000,https://www.zacks.com/stock/news/2196695/the-zacks-analyst-blog-highlights-biogen-prothena-ac-immunes-and-vaxxinity,BIIB,0.170878,Neutral,0.131235
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus,20231211T140600,https://www.zacks.com/stock/news/2196083/alzheimers-disease-space-evolves-in-2023-stocks-in-focus,BIIB,0.136888,Somewhat-Bullish,0.191134
"Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others - Biogen  ( NASDAQ:BIIB ) ",20231121T201625,https://www.benzinga.com/general/biotech/23/11/35901610/alzheimers-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-o,BIIB,0.229149,Neutral,-0.07556
Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research,20230515T093200,https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html,BIIB,0.069495,Neutral,0.0
Biogen  ( BIIB )  & Eisai's Lecanemab Secures EMA's MAA Acceptance,20230127T145700,https://www.zacks.com/stock/news/2045510/biogen-biib-eisais-lecanemab-secures-emas-maa-acceptance,BIIB,0.352223,Somewhat-Bullish,0.292167
"Stablix Appoints Douglas Williams, Ph.D., to Board of Directors",20230118T120047,https://www.benzinga.com/pressreleases/23/01/g30458105/stablix-appoints-douglas-williams-ph-d-to-board-of-directors,BIIB,0.063425,Neutral,-0.038049
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win - Biogen  ( NASDAQ:BIIB ) ,20220928T201722,https://www.benzinga.com/general/biotech/22/09/29061026/these-stocks-are-on-the-radar-after-biogen-eisais-surprising-alzheimers-trial-win,BIIB,0.112269,Neutral,-0.094787
"Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen",20220617T123100,https://www.zacks.com/stock/news/1940270/roche-alzheimers-candidate-failure-hurts-lilly-biogen,BIIB,0.31482,Neutral,-0.064442
Roche's experimental Alzheimer's drug crenezumab fails to prevent cognitive decline in people | The Financial Express,20220617T084432,https://www.financialexpress.com/healthcare/pharma-healthcare/roches-experimental-alzheimers-drug-crenezumab-fails-to-prevent-cognitive-decline-in-people/2564179/,BIIB,0.106164,Bearish,-0.436942
"The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK",20220616T140943,https://www.benzinga.com/general/biotech/22/06/27737919/the-daily-biotech-pulse-roches-alzheimers-drug-fails-advisors-back-pfizer-moderna-shots-for-young,BIIB,0.147607,Neutral,0.000232
"Alzheimer's Drugs Market Size [2022-2028] | Industry Size, Share, Growth, Trends & Forecast Analysis",20220505T112802,https://www.benzinga.com/pressreleases/22/05/g27015849/alzheimers-drugs-market-size-2022-2028-industry-size-share-growth-trends-forecast-analysis,BIIB,0.031454,Neutral,0.021912
"Alzheimer Drugs Market Size [2022-2028] | Industry Size, Share, Growth, Trends & Forecast Analysis",20220317T094130,https://www.benzinga.com/pressreleases/22/03/g26178322/alzheimer-drugs-market-size-2022-2028-industry-size-share-growth-trends-forecast-analysis,BIIB,0.072032,Neutral,-0.132033
BioCryst Pharmaceuticals  ( NASDAQ:BCRX )  - BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer,20220914T200110,https://www.benzinga.com/pressreleases/22/09/g28872104/biocryst-names-dr-bill-sheridan-chief-development-officer-and-appoints-dr-ryan-arnold-chief-medica,BIIB,0.06623,Neutral,0.044129
BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer,20220914T200100,https://www.globenewswire.com/news-release/2022/09/14/2516384/29446/en/BioCryst-Names-Dr-Bill-Sheridan-Chief-Development-Officer-and-Appoints-Dr-Ryan-Arnold-Chief-Medical-Officer.html,BIIB,0.069697,Neutral,0.045268
Co. Advancing Drug Class With Broad Potential,20220914T160429,https://www.investorideas.com/news/2022/biotech/09142Advancing-Drug-Class.asp,BIIB,0.041901,Neutral,0.0
ANNX: Insider Buying Sends Annexon Stock Higher. But Does That Make It a Buy?,20220721T131546,https://stocknews.com/news/annx-vrtx-amgn-biib-insider-buying-sends-annexon-stock-higher-but-does-that-make/,BIIB,0.137671,Neutral,0.041143
